Drugs / HMI-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05222178 | Jun 2022 → Sep 2023 | phenylketonuria | Homology Medicines, Inc | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMI-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05222178 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene” NCT05222178 ↗ |
| Route | Intravenous | “HMI-103 Administered Intravenously” NCT05222178 ↗ |